Latest revenue
$15.0M
as of 2026-03-31
Latest net income
$-96.2M
as of 2026-03-31
Net margin
-639.5%
as of 2026-03-31
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $1.76B
- Enterprise value
- $1.76B
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- —
- Dividend yield
- 0.0%
- 52-wk high
- $28.25
- 52-wk low
- $6.83
- Beta
- —
- Shares out
- 139.7M
5-year trend
What this company does
Item 1. Business Overview We are a leading clinical-stage gene editing company, focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. CRISPR/Cas9, an acronym for Clustered, Regularly Interspaced Short Palindromic Repeats (“CRISPR”)/CRISPR associated 9 (“Cas9”), is a technology for genome editing, the process of altering selected sequences of genomic deoxyribonucleic acid (“DNA”). To fully realize the transformative potential of CRISPR/Cas9-based technologies, we are building a full-spectrum gene editing company, by leveraging our modular platform, to advance in vivo and ex vivo therapies for diseases with high unmet need by pursuing two primary…
AI summary unavailable — showing raw filing excerpt
Generated from NTLA's filing dated 2024-02-22
Key risks
Item 1A. Risk Factors Investing in our common stock involves a high degree of risk. In evaluating us and our business, careful consideration should be given to the following risk factors, in addition to the other information set forth in this Annual Report on Form 10-K for the year ended December 31, 2025 and in other documents that we file with the Securities and Exchange Commission (“SEC”). If any of the following risks and uncertainties actually occurs, our business, prospects, financial condition and results of operations could be materially and adversely affected. The risks described below are not intended to be exhaustive and are not the only risks facing us. New risk factors can…
AI summary unavailable — showing raw filing excerpt
Generated from NTLA's filing dated 2024-02-22
Profitability
Operating margin
-651.7%
29.4%Net margin
-609.9%
32.0%Return on equity
-61.5%
24.4%Return on assets
-49.0%
12.5%Leverage
Debt / equity
0.25×
89.6%Debt / assets
20.3%
71.4%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $15.0M | -9.5% | $-96.2M | +15.8% | -639.5% |
Q4 2025 2025-12-31 | $23.0M | +78.8% | $-95.8M | +25.7% | -416.2% |
Q3 2025 2025-09-30 | $13.8M | +51.3% | $-101.3M | +25.3% | -735.2% |
Q2 2025 2025-06-30 | $14.2M | +104.8% | $-101.3M | +31.1% | -710.8% |
Q1 2025 2025-03-31 | $16.6M | -42.5% | $-114.3M | -6.4% | -687.6% |
Q4 2024 2024-12-31 | $12.9M | — | $-128.9M | — | -1001.2% |
Q3 2024 2024-09-30 | $9.1M | -24.0% | $-135.7M | -11.0% | -1489.5% |
Q2 2024 2024-06-30 | $7.0M | -48.8% | $-147.0M | -18.8% | -2112.6% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
In Vitro & In Vivo Diagnostic Substances · SIC 2835
Your notes
Keep private notes on NTLA — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$2.4M
Insider selling
$1.8M
Net activity
+$570.2K
Distinct insiders
10
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns NTLA
Institutional value
$854.5M
Total shares held
67.4M
Distinct holders
186
-104 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | ARK Investment Management LLC | 14.5M | $186.0M | +301.9K (+2.1%) | Added |
| 2 | BlackRock, Inc. | 12.2M | $155.8M | +1.9M (+18.3%) | Added |
| 3 | VANGUARD PORTFOLIO MANAGEMENT LLC | 6.2M | $79.8M | — | New |
| 4 | VANGUARD CAPITAL MANAGEMENT LLC | 5.1M | $65.2M | — | New |
| 5 | REGENERON PHARMACEUTICALS, INC. | 3.7M | $47.5M | +0 (+0.0%) | No change |
| 6 | UBS Group AG | 2.7M | $34.5M | +1.8M (+212.9%) | Added |
| 7 | DIMENSIONAL FUND ADVISORS LP | 2.3M | $29.7M | +386.3K (+20.0%) | Added |
| 8 | Sumitomo Mitsui Trust Group, Inc. | 2.0M | $25.3M | -219.4K (-10.0%) | Trimmed |
| 9 | Nikko Asset Management Americas, Inc. | 2.0M | $25.3M | -219.4K (-10.0%) | Trimmed |
| 10 | Contrarius Group Holdings Ltd | 1.9M | $24.5M | +1.2M (+167.6%) | Added |
| 11 | JUPITER ASSET MANAGEMENT LTD | 1.8M | $22.8M | +743.1K (+71.6%) | Added |
| 12 | STIFEL FINANCIAL CORP | 1.0M | $13.0M | +81.3K (+8.7%) | Added |
| 13 | Connor, Clark & Lunn Investment Management Ltd. | 748.6K | $9.6M | +488.9K (+188.3%) | Added |
| 14 | VANGUARD FIDUCIARY TRUST CO | 748.1K | $9.6M | — | New |
| 15 | IQ EQ FUND MANAGEMENT (IRELAND) Ltd | 724.3K | $9.3M | -7.1K (-1.0%) | Trimmed |
| 16 | Marex Group plc | 623.6K | $8.0M | -1 (-0.0%) | Trimmed |
| 17 | BNP PARIBAS FINANCIAL MARKETS | 579.4K | $7.4M | -11.8K (-2.0%) | Trimmed |
| 18 | JPMORGAN CHASE & CO | 548.5K | $6.4M | -195.2K (-26.2%) | Trimmed |
| 19 | Invesco Ltd. | 434.8K | $5.6M | +1.5K (+0.3%) | Added |
| 20 | HIMENSION CAPITAL (SINGAPORE) PTE. LTD. | 429.5K | $5.5M | -149.0K (-25.8%) | Trimmed |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once NTLA's latest filing finishes processing.